In addition, ACE2 is an enzyme regulator of the Renin-Angiotensin-System (RAS), a disease relevant system involved in COVID-19 and more generally a wide group of acute lung disorders and cardiovascular diseases. Based on its function to negatively regulate RAS, APN01 can reduce injury to multiple organs including the lung, kidneys and the heart, and reduces disease mediated organ pathology.
Furthermore, in a unique triple approach, APN01 triggers reduction of inflammatory cytokines and chemokines, both of which play an important role in lung injury and cytokine storm.
Taken together, APN01´s triple mode of action has a unique advantage compared to virtually all other treatments by providing the best scientific rational among specific therapeutics for COVID-19, surpassing other treatment options by acting at all relevant disease stages from the first viral infection to the development of severe lung injury and the consequences of the infection.
The safety and tolerability of APN01 has been shown in several Phase 1 and Phase 2 trials.